Principia Biopharma Inc

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Trial enrolled patients ahead of originally anticipated timeline despite COVID-19 pandemic Trial enrolled patients ahead of originally anticipated timeline despite COVID-19 pandemic

Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib

Sanofi

Sanofi completes Principia Biopharma Inc. acquisition

Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Principia Biopharma Inc. (“Principia”, NASDAQ: PRNB) has expired.

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.

SOUTH SAN FRANCISCO, Calif., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD). 

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

SAN DIEGO, Sept. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc.

(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN

Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRINCIPIA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Principia Biopharma Inc. - PRNB

Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Principia (PRNB) Looks Good: Stock Adds 9.4% in Session

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Principia Biopharma Inc.

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Principia Biopharma Inc. to Sanofi

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Principia Biopharma Inc.

STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Principia Biopharma Inc. - PRNB

This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.

Sanofi Acquiring Principia Biopharma for $3.7 Billion

TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.

Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma

Principia Biopharma Inc. (NASDAQ: PRNB) shares jumped to start out the week after it was announced that it would be acquired by Sanofi (NASDAQ: SNY).

What Sanofi Is Adding to Its Portfolio With This New Acquisition

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B

Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma.
The post Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts appeared first on Investor's Business Daily.

Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts

Sanofi S.A. (EPA: SAN) expressed plans of acquiring Principia Biopharma Inc.

Sanofi to acquire U.S. Principia Biopharma Inc. for £2.82 billion

Sanofi SA (NASDAQ: SNY) will acquire Principia Biopharma Inc (NASDAQ: PRNB) for $3.68 billion in cash, the two companies announced Monday.

Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B

French health care company Sanofi has agreed to buy U.S. company Principia Biopharma for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

French group Sanofi to buy U.S. firm Principia Biopharma for $3.7 billion

Sanofi to acquire Principia Biopharma

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Analysts Estimate Principia Biopharma Inc. (PRNB) to Report a Decline in Earnings: What to Look Out for

Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%

Dosing of Patient Will Trigger $50 Million Milestone Payment Dosing of Patient Will Trigger $50 Million Milestone Payment

Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis

Clear dose-response combined with decreased daily corticosteroid usage

News for Principia Biopharma Inc Stock (PRNB)